Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
Evaxion Biotech has completed dosing in its Phase 2 trial of EVX-01, a personalized cancer vaccine, for advanced melanoma treatment.
Evaxion Biotech utilizes its AI platform, AI Immunology, for rapid vaccine discovery and development, targeting cancer and infectious diseases.
Evaxion Biotech's AI-Immunology™ platform demonstrates strong ability to select clinically relevant vaccine targets across three clinical trials.
Evaxion Biotech's EVX-01, combined with pembrolizumab, demonstrated a 69% Overall Response Rate in advanced melanoma patients in a Phase 2 trial.
Evaxion Biotech's EVX-01, combined with pembrolizumab, demonstrates a 69% Overall Response Rate (ORR) in advanced melanoma patients.